Literature DB >> 8039622

Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients.

V Balan1, W Baldus, V Fairbanks, V Michels, M Burritt, G Klee.   

Abstract

BACKGROUND/AIMS: Current emphasis in hemochromatosis has focused on early detection and treatment to prevent permanent liver damage and hepatocellular carcinoma. Thus far, only normal population and high-risk groups have been screened but not patients seeking medical care.
METHODS: Serum iron levels were determined in consecutive fasting blood samples collected in the morning from 12,258 Mayo Clinic patients.
RESULTS: One hundred twenty-seven patients had an initial serum iron concentration > or = 180 micrograms/dL. Eight patients (age, 38-71 years; 7 men and 1 woman) had transferrin saturation > or = 62% (range, 84-99) and serum ferritin value > or = 400 micrograms/L (range, 457-4004) with no other explanation for the abnormal iron test results. Three patients (2 male and 1 female) had markedly elevated hepatic iron concentration (range, 11,080-29,719 micrograms/g dry wt) and hepatic iron index (range, 2.9-8.4) indicative of homozygous hemochromatosis. One patient who refused liver biopsy had 7 g of iron removed by phlebotomy and is likely homozygous. Two patients had hepatic iron indices < 1.5 and are probably heterozygous. The genetic status of 1 patient is indeterminate, and 1 patient with normal hepatic iron concentration and hepatic iron index had chronic active hepatitis. None had cirrhosis, diabetes, or cardiomyopathy. No patients with hemochromatosis would have been detected without this study.
CONCLUSIONS: The yield in this study, 0.33 cases of 1000 screened, is approximately one tenth of the predicted homozygote frequency by recent estimates. Even at this yield, screening appears cost-effective.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039622     DOI: 10.1016/0016-5085(94)90171-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

1.  Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Yi-Chuan Yu; Hung N Luu; Renwei Wang; Claire E Thomas; Nancy W Glynn; Ada O Youk; Jaideep Behari; Jian-Min Yuan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-10-14       Impact factor: 4.090

2.  The significance of haemochromatosis gene mutations in the general population: implications for screening.

Authors:  M J Burt; P M George; J D Upton; J A Collett; C M Frampton; T M Chapman; T A Walmsley; B A Chapman
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

3.  Screening for hemochromatosis in Turkey.

Authors:  Hakan Bozkaya; Mehmet Bektas; Olga Metin; Ozlem Erkan; Dicle Ibrahimoglu; Klara Dalva; Filiz Akbiyik; Selim Gurel; Abdurrahman Mithat Bozdayi; Cemal Akay; Cihan Yurdaydin; Onder Aslan; Ozden Uzunalimoglu
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

Review 4.  Inherited liver diseases in adults.

Authors:  A Kumar; C A Riely
Journal:  West J Med       Date:  1995-10

5.  Serum or plasma ferritin concentration as an index of iron deficiency and overload.

Authors:  Maria Nieves Garcia-Casal; Sant-Rayn Pasricha; Ricardo X Martinez; Lucero Lopez-Perez; Juan Pablo Peña-Rosas
Journal:  Cochrane Database Syst Rev       Date:  2021-05-24

6.  Burden of iron overload among non-chronically blood transfused preschool children with sickle cell anaemia.

Authors:  Akodu Samuel Olufemi; Adekanmbi Abiodun Folashade; Ogunlesi Tinuade Adetutu
Journal:  Afr Health Sci       Date:  2021-06       Impact factor: 0.927

7.  The adaptability of red blood cells.

Authors:  Etheresia Pretorius
Journal:  Cardiovasc Diabetol       Date:  2013-04-11       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.